A Dose-Finding Study of GSK2894512 Cream in Subjects With Plaque Psoriasis

Inclusion Criteria:

- Male or female between 18 to 65 years of age inclusive, at the time of signing the
informed consent.

- Confirmed clinical diagnosis of chronic stable plaque psoriasis for >=6 months.

- Body surface area involvement >=1% and <=15%, excluding scalp, at Screening and
Baseline.

- A PGA of psoriasis score >=2 at Baseline.

- One target plaque located on the trunk or proximal parts of extremities (excluding
knees, elbows, and intertriginous areas) that is at least 3 (centimetre) cm х 3 cm in
size at Screening and Baseline with a severity representative of the subject's overall
disease.

- A female subject is eligible to participate if she is not pregnant (as confirmed by a
negative urine human chorionic gonadotrophin test), not lactating, and at least one of
the following conditions applies: Non-reproductive potential defined as: 1)
Pre-menopausal females with one of the following procedures documented: tubal
ligation; hysteroscopic tubal occlusion procedure with follow-up confirmation of
bilateral tubal occlusion; hysterectomy; bilateral oophorectomy. 2) Post-menopausal
defined as 12 months of spontaneous amenorrhea (in questionable cases a blood sample
with simultaneous follicle stimulating hormone and estradiol levels consistent with
menopause and falling into the central laboratory's postmenopausal reference range is
confirmatory). Females on hormone replacement therapy (HRT) and whose menopausal
status is in doubt are required to use one of the highly effective contraception
methods if they wish to continue their HRT during the study. Otherwise, they must
discontinue HRT to allow confirmation of post-menopausal status prior to study
enrolment; Reproductive potential and agrees to follow one of the options listed in
the modified list of highly effective methods for avoiding pregnancy in females of
reproductive potential from 30 days prior to the first dose of study medication and
until (at least five terminal half-lives OR until any continuing pharmacologic effect
has ended, whichever is longer) after the last dose of study medication and completion
of the follow-up visit.

Exclusion Criteria:

- Any sign of infection of any of the psoriatic lesions.

- A history or ongoing serious illness or medical, physical, or psychiatric condition(s)
that, in the investigator's opinion, may interfere with the subject's completion of
the study.

- Known hypersensitivity to the study treatment excipients, or a history of drug or
other allergy that, in the opinion of the investigator, contraindicates participation.

- Current or chronic history of liver disease, known hepatic or biliary abnormalities
(with the exception of Gilbert's syndrome or asymptomatic gallstones), presence of
hepatitis B surface antigen, or positive hepatitis C antibody test result within 3
months of screening.

- Liver function tests: alanine aminotransferase >=2x upper limit of normal (ULN);
alkaline phosphatase and bilirubin >1.5xULN (isolated bilirubin >1.5xULN is acceptable
if bilirubin is fractionated and direct bilirubin <35%).

- QTc >=450 milliseconds (msec) or QTc >=480 msec for subjects with bundle branch block.

NOTES: The QTc is the QT interval corrected for heart rate according to Fridericia's
formula (QTcF), with machine over-read. The QTc should be based on a single ECG obtained
over a brief recording period. If QTc is outside of the threshold value, triplicate ECGs
may be performed with the QTc values averaged.

- Ultraviolet (UV) light therapy or prolonged exposure to natural or artificial sources
of UV radiation (eg, sunlight or tanning booth) within 4 weeks prior to the baseline
visit and/or intention to have such exposure during the study, which is thought by the
investigator to potentially impact the subject's psoriasis.

- Used any of the following treatments within the indicated washout period before the
baseline visit: 1) 12 weeks or 5 half-lives (whichever is longer) - biologic agents
(eg, 24 weeks for alefacept, 12 weeks for etanercept, 15 weeks for ustekinumab); 2) 12
weeks - oral retinoids (eg, acitretin or isotretinoin); 3) 8 weeks - cyclosporin,
interferon, methotrexate, other systemic immunosuppressive or immunomodulating agents,
or psoralen plus UVA light treatment; 4) 4 weeks - systemic corticosteroids or
adrenocorticotropic hormone analogs; 5) 2 weeks - immunizations; drugs known to
possibly worsen psoriasis, such as beta-blockers (eg, propranolol), lithium, iodides,
angiotensin-converting enzyme inhibitors, and indomethacin, unless on a stable dose
for >12 weeks; 6) 2 weeks - topical treatments: corticosteroids, immunomodulators,
anthralin (dithranol), Vitamin D derivatives, retinoids, or coal tar (used on the
body).

- Participated in a clinical study and received an investigational product within the
following time period prior to the baseline visit: 4 weeks, 5 half-lives, or twice the
duration of the biological effect of the investigational product (whichever is
longer).

- History of alcohol or other substance abuse within the last 2 years.

- Participated in a previous study using GSK2894512 (or WBI-1001).